The BPCIA Transition: Products, Patents And Exclusivities

 
• By Sue Sutter

Pink Sheet infographic looks at the 95 NDAs moving from regulation as drugs to biologics on 23 March; list includes 27 insulin products, seven of which have unexpired exclusivity that will not carry over when they are delisted from the 'Orange Book.'

March 23, Empty Vintage background.
95 NDAs are headed for a regulatory change on 23 March. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics